Corcept Therapeutics reported $102.07M in Gross Profit on Sales for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
TG Therapeutics TGTX:US 571K 1.21M
Acadia Pharmaceuticals ACAD:US $ 131.9M 19.38M
Ardelyx ARDX:US $ 2.39M 2M
Aurora Cannabis Inc ACB:CN -22244000 30.69M
Biomarin Pharmaceutical BMRN:US $ 410.67M 8.28M
Bristol Myers Squibb BMY:US $ 9210M 33M
Canopy Growth Corp WEED:CN C$ -1392000 157.85M
Corcept Therapeutics CORT:US $ 102.07M 9.63M
Depomed DEPO:US $ 30.6M 2.14M
Eli Lilly And LLY:US $ 5057.5M 680.4M
Esperion Therapeutics ESPR:US $ 9.66M 2.05M
Johnson & Johnson JNJ:US $ 16101M 273M
Knight Therapeutics Inc GUD:CN C$ 38.3M 5.82M
Lannett LCI:US $ 7.86M 4.78M
Merk MRK:US $ 10895M 328M
Nektar Therapeutics NKTR:US $ 16.47M 3.04M
Novartis NOVN:VX 9.34B 277M
Novartis NVS:US $ 9336M 277M
Pacira Pharmaceuticals PCRX:US $ 118.78M 3.13M
Pfizer PFE:US $ 19071M 3420M
Supernus Pharmaceuticals SUPN:US $ 149.59M 15.02M